While the specificity of anti-IL-17 therapies may limit their effectiveness in conditions where multiple inflammatory pathways are involved, combining anti-IL-17 therapies with other anti-inflammatory treatments in respiratory diseases holds potential for synergistic effects. Here, IL17A is linked to respiratory system disorder.